Nutra Pharma Corporation (NPHC) Proves Strength in Numbers Can Make a Difference
A biotechnology company, Nutra Pharma Corporation (OTCQB: NPHC) focuses on acquiring, licensing, and commercializing pharmaceutical products and technologies. The company concentrates on preventing and treating neurological disorders, cancer, and autoimmune and infectious diseases. Currently, Nutra Pharma offers Nyloxin® and Nyloxin® Extra Strength, the only non-narcotic and non-addictive treatments for severe pain that are sold over-the-counter. The company also markets Pet Pain-Away, an over-the-counter pain reliever for beloved pets. Furthermore, its multiple sclerosis and HIV applications are ready to move into phase II clinical trials. Through its two wholly-owned subsidiaries, Designer Diagnostics and ReceptoPharm, Nutra Pharma has already been able to contribute to the biopharmaceutical field in tremendous ways.
ReceptoPharm, the “drug discovery arm” for Nutra Pharma, develops therapeutic protein products that help prevent and treat viral, autoimmune, and neurological diseases in humans. For these products, the company focuses on receptor-binding proteins found in nature, specifically cobra venom. The two leading products created by ReceptoPharm are RPI-MN and RPI-78M. The first hinders neurological damaging viruses like encephalitis and HIV. The second treats neurological disorders like multiple sclerosis and adrenomyeloneuropathy. Both of these products are easily administered, stabilized, and cause no severe side effects.
Established in 2005, Designer Diagnostics develops and markets test kits that can identify harmful disease-causing bacteria quickly. This early detection allows doctors to administer treatments immediately to prevent the spreading of disease. The company’s diagnostic tests can detect harmful nontuberculous mycobacteria, which can lead to tuberculosis, nocardia, pseudomonas, and mycobacterium avium complex. Fortunately, these tests can detect diseases in less than a week, have a long shelf life, and can be stored in almost any environment. Plus, they are cost-effective and can integrate easily with any laboratory, which makes prevention both feasible and accessible.
Nutra Pharma, backed by its subsidiaries, aims to deliver bio-pharmaceutical breakthroughs that proactively increase the quality of life of people with debilitating diseases. By continuing its business model of acquiring biotechnological companies with similar goals and interests, the company stands to make an enormous impact in the pharmaceutical industry.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
A biotechnology company, Nutra Pharma Corporation (OTCQB: NPHC) focuses on acquiring, licensing, and commercializing pharmaceutical products and technologies. The company concentrates on preventing and treating neurological disorders, cancer, and autoimmune and infectious diseases. Currently, Nutra Pharma offers Nyloxin® and Nyloxin® Extra Strength, the only non-narcotic and non-addictive treatments for severe pain that are sold over-the-counter. The company also markets Pet Pain-Away, an over-the-counter pain reliever for beloved pets. Furthermore, its multiple sclerosis and HIV applications are ready to move into phase II clinical trials. Through its two wholly-owned subsidiaries, Designer Diagnostics and ReceptoPharm, Nutra Pharma has already been able to contribute to the biopharmaceutical field in tremendous ways.
ReceptoPharm, the “drug discovery arm” for Nutra Pharma, develops therapeutic protein products that help prevent and treat viral, autoimmune, and neurological diseases in humans. For these products, the company focuses on receptor-binding proteins found in nature, specifically cobra venom. The two leading products created by ReceptoPharm are RPI-MN and RPI-78M. The first hinders neurological damaging viruses like encephalitis and HIV. The second treats neurological disorders like multiple sclerosis and adrenomyeloneuropathy. Both of these products are easily administered, stabilized, and cause no severe side effects.
Established in 2005, Designer Diagnostics develops and markets test kits that can identify harmful disease-causing bacteria quickly. This early detection allows doctors to administer treatments immediately to prevent the spreading of disease. The company’s diagnostic tests can detect harmful nontuberculous mycobacteria, which can lead to tuberculosis, nocardia, pseudomonas, and mycobacterium avium complex. Fortunately, these tests can detect diseases in less than a week, have a long shelf life, and can be stored in almost any environment. Plus, they are cost-effective and can integrate easily with any laboratory, which makes prevention both feasible and accessible.
Nutra Pharma, backed by its subsidiaries, aims to deliver bio-pharmaceutical breakthroughs that proactively increase the quality of life of people with debilitating diseases. By continuing its business model of acquiring biotechnological companies with similar goals and interests, the company stands to make an enormous impact in the pharmaceutical industry.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
